Fig. 3From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysisFunnel plot. a. Publication bias of overall response rate of rituximab in AIHA and MAHA. b Publication bias of complete response rate of rituximab in AIHA and MAHA. c Relapse rate of rituximab in AIHA and MAHA. d Publication bias of relative overall response rate of rituximab in AIHA and MAHA. e Publication bias of relative complete response rate of rituximab in AIHA and MAHA. f Publication bias of relative relapse rate of rituximab in AIHA and MAHABack to article page